Literature DB >> 30082487

10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma.

Lei Chen1, Yuan Zhang1, Shu-Zhen Lai2, Wen-Fei Li1, Wei-Han Hu1, Rui Sun1, Li-Zhi Liu3, Fan Zhang4, Hao Peng1, Xiao-Jing Du1, Ai-Hua Lin5, Ying Sun1, Jun Ma6.   

Abstract

BACKGROUND: The purpose of this study was to verify 10-year results of survival and late toxicities and assess the ultimate therapeutic ratio of intensity-modulated radiotherapy (IMRT) versus two-dimensional radiotherapy (2DRT) in patients with nasopharyngeal carcinoma (NPC).
MATERIALS AND METHODS: We retrospectively reviewed the data from 1,276 patients with nonmetastatic NPC who received IMRT or 2DRT from January 2003 to December 2006.
RESULTS: Of the 1,276 patients, 512 were treated with IMRT and 764 with 2DRT. Median follow-up was 115 months. At 10 years, the IMRT group demonstrated significantly better results than the 2DRT group in local failure-free survival (L-FFS; 90% vs. 84%; hazard ratio [HR], 0.57, 95% confidence interval [CI], 0.40-0.81; p = .001), failure-free survival (FFS; 69% vs. 58%; HR, 0.69, 95% CI, 0.57-0.83; p < .001), and overall survival (OS; 75% vs. 63%; HR, 0.62, 95% CI, 0.51-0.77; p < .001). Subgroup multivariate analyses showed that radiotherapeutic technique (IMRT vs. 2DRT) remained an independent prognostic factor for L-FFS in the T1 subgroup (HR, 0.30; 95% CI, 0.11-0.80; p = .02); for FFS in the stage II subgroup (HR, 0.42; 95% CI, 0.24-0.73; p = .002); and for OS in the stage I (HR, 0.20; 95% CI, 0.04-0.96; p = .04), stage II (HR, 0.39; 95% CI, 0.21-0.75; p = .004), and stage IVA-B (HR, 0.74, 95% CI, 0.56-0.98; p = .04) subgroups. The incidence of grade 3-4 temporal lobe necrosis, cranial neuropathy, eye damage, ear damage, neck soft tissue damage, trismus, and dry mouth was significantly lower in the IMRT group than in the 2DRT group.
CONCLUSION: IMRT demonstrated an improved ultimate therapeutic ratio compared with 2DRT in patients with NPC after a 10-year follow-up, with significant improvement of L-FFS, FFS, and OS and decrease in most late toxicities. IMPLICATIONS FOR PRACTICE: The ultimate therapeutic ratio of intensity-modulated radiotherapy versus two-dimensional radiotherapy in patients with nasopharyngeal carcinoma is unclear. In this retrospective study of 1,276 patients with nonmetastatic nasopharyngeal carcinoma with a follow-up of 115 months, intensity-modulated radiotherapy demonstrated an improved ultimate therapeutic ratio compared with two-dimensional radiotherapy, with significant improvement of local failure-free survival, failure-free survival, and overall survival and decrease in most late toxicities and noncancer deaths. However, distant control remains insufficient with this treatment modality. © AlphaMed Press 2018.

Entities:  

Keywords:  10‐year results; Intensity‐modulated radiotherapy; Nasopharyngeal carcinoma; Therapeutic ratio; Two‐dimensional radiotherapy

Year:  2018        PMID: 30082487      PMCID: PMC6324627          DOI: 10.1634/theoncologist.2017-0577

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  22 in total

1.  How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?

Authors:  Shu-Zhen Lai; Wen-Fei Li; Lei Chen; Wei Luo; Yuan-Yuan Chen; Li-Zhi Liu; Ying Sun; Ai-Hua Lin; Meng-Zhong Liu; Jun Ma
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-17       Impact factor: 7.038

Review 2.  Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials.

Authors:  Yu-Pei Chen; Ying Sun; Lei Chen; Yan-Ping Mao; Ling-Long Tang; Wen-Fei Li; Xu Liu; Wen-Na Zhang; Guan-Qun Zhou; Rui Guo; Ai-Hua Lin; Jun Ma
Journal:  Radiother Oncol       Date:  2015-08-01       Impact factor: 6.280

3.  Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes.

Authors:  Gary D Lewis; Emma B Holliday; Esengul Kocak-Uzel; Mike Hernandez; Adam S Garden; David I Rosenthal; Steven J Frank
Journal:  Head Neck       Date:  2015-12-26       Impact factor: 3.147

4.  Salvage endoscopic nasopharyngectomy and intensity-modulated radiotherapy versus conventional radiotherapy in treating locally recurrent nasopharyngeal carcinoma.

Authors:  Xiong Zou; Fei Han; Wen-Juan Ma; Man-Quan Deng; Rou Jiang; Ling Guo; Qing Liu; Hai-Qiang Mai; Ming-Huang Hong; Ming-Yuan Chen
Journal:  Head Neck       Date:  2014-07-11       Impact factor: 3.147

5.  Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience.

Authors:  Suzanne L Wolden; William C Chen; David G Pfister; Dennis H Kraus; Sean L Berry; Michael J Zelefsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-02       Impact factor: 7.038

6.  Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.

Authors:  Nancy Y Lee; Qiang Zhang; David G Pfister; John Kim; Adam S Garden; James Mechalakos; Kenneth Hu; Quynh T Le; A Dimitrios Colevas; Bonnie S Glisson; Anthony Tc Chan; K Kian Ang
Journal:  Lancet Oncol       Date:  2011-12-15       Impact factor: 41.316

7.  Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.

Authors:  Ying Sun; Wen-Fei Li; Nian-Yong Chen; Ning Zhang; Guo-Qing Hu; Fang-Yun Xie; Yan Sun; Xiao-Zhong Chen; Jin-Gao Li; Xiao-Dong Zhu; Chao-Su Hu; Xiang-Ying Xu; Yuan-Yuan Chen; Wei-Han Hu; Ling Guo; Hao-Yuan Mo; Lei Chen; Yan-Ping Mao; Rui Sun; Ping Ai; Shao-Bo Liang; Guo-Xian Long; Bao-Min Zheng; Xing-Lai Feng; Xiao-Chang Gong; Ling Li; Chun-Ying Shen; Jian-Yu Xu; Ying Guo; Yu-Ming Chen; Fan Zhang; Li Lin; Ling-Long Tang; Meng-Zhong Liu; Jun Ma
Journal:  Lancet Oncol       Date:  2016-09-27       Impact factor: 41.316

8.  Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma.

Authors:  Jeremy Setton; James Han; Danita Kannarunimit; Yen-Ruh Wuu; Stephen A Rosenberg; Carl DeSelm; Suzanne L Wolden; C Jillian Tsai; Sean M McBride; Nadeem Riaz; Nancy Y Lee
Journal:  Oral Oncol       Date:  2015-12-07       Impact factor: 5.337

9.  Extension of local disease in nasopharyngeal carcinoma detected by magnetic resonance imaging: improvement of clinical target volume delineation.

Authors:  Shao-Bo Liang; Ying Sun; Li-Zhi Liu; Yong Chen; Lei Chen; Yan-Ping Mao; Ling-Long Tang; Li Tian; Ai-Hua Lin; Meng-Zhong Liu; Li Li; Jun Ma
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-27       Impact factor: 7.038

10.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

View more
  17 in total

1.  Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients.

Authors:  Chao Deng; Na Zhang; Shun Jiang; Haixia Zhang; Jin'an Ma; Wen Zou; Xianling Liu; Chunhong Hu; Tao Hou
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

2.  A New Model for Predicting Hypothyroidism After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma.

Authors:  Liang Peng; Yan-Ping Mao; Cheng-Long Huang; Rui Guo; Jun Ma; Wei-Ping Wen; Ling-Long Tang
Journal:  Front Oncol       Date:  2020-09-25       Impact factor: 6.244

3.  Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion.

Authors:  Shufang Liao; Yuan Xie; Yi Feng; Yuanyuan Zhou; Yufei Pan; Jinfang Fan; Jinglin Mi; Xiaoli Qin; Dacheng Yao; Wei Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-01       Impact factor: 4.553

4.  Necessity of concurrent chemotherapy in N2-3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥3 cycles followed by intensity-modulated radiotherapy.

Authors:  Hui Chang; Liang Peng; Ya-Lan Tao; Chen Chen; Wei-Wei Xiao; Yong-Hong Hu; Yuan-Hong Gao
Journal:  Cancer Med       Date:  2019-04-21       Impact factor: 4.452

5.  DW-MRI-Guided Dose Escalation Improves Local Control of Locally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy.

Authors:  Guohui Xu; Jinyi Lang; Yecai Huang; Mei Feng; Xuegang Yang; Jie Zhou; Lu Li; Ke Xu
Journal:  Cancer Manag Res       Date:  2020-05-06       Impact factor: 3.989

6.  Risk stratification for nasopharyngeal carcinoma: a real-world study based on locoregional extension patterns and Epstein-Barr virus DNA load.

Authors:  Lu-Lu Zhang; Meng-Yao Huang; Ke-Xin Wang; Di Song; Ting Wang; Li-Yue Sun; Jian-Yong Shao
Journal:  Ther Adv Med Oncol       Date:  2020-06-12       Impact factor: 8.168

7.  Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.

Authors:  Wanxia Li; Jing Chen; Bijun Liang; Zonghua Li; Junzheng Li; Xiaofei Yuan; Shuting Wu; Fangfang Zeng; Xinyu Peng; Yanfei Li; Juan Lu; Feipeng Zhao; Xiong Liu
Journal:  Cancer Med       Date:  2020-12-30       Impact factor: 4.452

8.  Prognostic Value of Clinical Biochemistry-Based Indexes in Nasopharyngeal Carcinoma.

Authors:  Xiaojiao Zeng; Guohong Liu; Yunbao Pan; Yirong Li
Journal:  Front Oncol       Date:  2020-03-06       Impact factor: 6.244

9.  Temporal lobe microstructural abnormalities in patients with nasopharyngeal carcinoma quantitatively evaluated by high-resolution DWI and DKI after concurrent chemoradiotherapy.

Authors:  Gang Wu; Rui-Rui Li; Priya S Balasubramanian; Meng-Meng Li; Kai Yang; Wei-Yuan Huang; Feng Chen
Journal:  Clin Transl Radiat Oncol       Date:  2019-12-25

10.  Undifferentiated nasopharyngeal cancer extending to maxillary sinus: a case report.

Authors:  Mohamed Beghdad; Amine Mkhatri; Yassine Harmoumi; Meriem Doumiri; Sami Rouadi; Reda Abada; Mohamed Roubal; El Benna Naima; Mohamed Mahtar
Journal:  Pan Afr Med J       Date:  2020-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.